Peter Schulam, MD, PhD, reviews the controversy surrounding prostate cancer screening, explains the literature that led to the United States Preventive Services Task Force (USPSTF) coming out with a C recommendation for prostate cancer screening, and notes the limitations in the current standard of transrectal ultrasound (TRUS) biopsy. He then discusses how MRI fusion biopsy could address these limitations.
Read More
Larissa Rodriguez, MD, discusses risk factors of recurrent urinary tract infections after midurethral sling surgery, when and how to evaluate patients that present with recurrent infections, indications for sling removal, and the evidence needed to prove that this is a safe and beneficial option.
Read More
Riccardo Autorino, MD, PhD, FEBU, defines oligometastatic prostate cancer, a newly-explored concept in the urological community. He discusses whether or not radical prostatectomy offers significant oncological benefits that outweigh the risk of complications and negative impacts on urinary function and QOL outcomes for patients in this stage.
Read More
Tobias S. Kohler MD, MPH, discusses the literature linking erectile dysfunction to systemic vascular disease, the corollary relationship between vascular disease and its treatment to erectile dysfunction, and pudendal artery stenting.
Read More
Peter Schulam MD, PhD, emphasizes the importance of staging renal tumors based on weighted risk, including risk of metastases, histologic subtypes, and adverse pathologic characteristics, and not simply mass size. This is essential when considering partial nephrectomy, radical nephrectomy, active surveillance, ablative techniques, or other management options for individual patients.
Read More